INTRODUCTION
Traditionally, drug delivery systems have focused on constant/sustained drug output with the objective of minimizing peaks and valleys of drug concentrations in the body to optimize drug efficacy and to reduce adverse effects. Diseases where a constant drug levels are not preferred, but needs a pulse of therapeutic concentration in a periodic manner acts as a push for the development of "Chronopharmaceutical Drug Delivery Systems" [1] [2] . The Montelukast Sodium is Leukotriene receptor antagonist used for the maintenance treatment of asthma, chronic asthma attacks and to relive symptoms of seasonal allergies.
Asthma is chronic inflammatory disease of the airways, characterized by hyper responsiveness to variety of stimuli. The role of circadian rhythm in the photogenesis and treatment of asthma indicates that airway resistance increases progressively at night in asthmatic patient. Circadian changes are seen in normal lung function, which reaches in low point in the early morning hours. The worsening of asthma at night, commonly referred to as Nocturnal Asthma (NA). A drug delivery system administered at bedtime but releasing drug during morning hours would be ideal in this case. Nocturnal Asthma is variable exacerbation of underlying asthma condition associated with increase in symptoms, need for medication, airway responsiveness, and/or worsening of lung function 4 .Press coated tablets (PCTs) gained wide interest 'claiming some advantages over regular and (pan-) coated tablets, such as to protect hygroscopic, light-sensitive or oxygen-labile drugs from environmental-atmospheric ill effects or decomposition of acid-labile drugs by gastric fluids; to separate incompatible drugs from each other; to achieve a sustained release in that the drug in the core is embedded in waxes or fats constituting a depot; to protect the gastric mucosa from irritation by certain drugs by using enteric coating material in the outer press-coating granules; or to achieve intermittent release by incorporating one portion of drug in the core and the other in the coat, separated by a film-coat or a second press-coat drawbacks of the press-coating technique are the multistep processes involved, and the requirement for reliable and reproducible central positioning of the core tablet within press-coated tablet (PCT) [5] [6] [7] [8] . The aim of the study was to develop and physico-chemically characterize pulsatile delivery tablet of Montelukast using different polymers. Montelukast has a biological half-life of about 2.5-5.5 hrs and 64 % bioavailability. Development of pulse release formulation of Montelukast can be advantageous, that can provide specific lag time and increase compliancy of the dosage form towards patient's side. Asthma peak is more in early morning so it is not feasible to take tablet in midnight so pulsatile delivery is preferred one because this type of tablet should be taken after dinner which deliver drug immediately after a specified lag time about 4-5hrs. So drug may available (right time, right site) in blood circulation about 3 o'clock so it is available to protect from early morning asthma due to its 4-6 hrs. of half-life 3 .
So development of formulation consisted of a rapidly disintegrating core tablet press coated by a barrier layer consisting of varying concentrations of Xanthan Gum, Polyox303, Ethyl cellulose and Hydroxypropylmethyl cellulose. Ethylcellulose and hydrophilic polymers are used as a rate controlling polymer to achieve desired lag time. 
MATERIALS AND METHODS

Drug
Preparation of core tablets:
The inner-core tablets were prepared using direct compression to perform various release kinetics, depending upon the release mechanism involved. The composition of different formulations were prepared applying design expert software factorial design in which varying amounts of superdisintegrants, type of superdisintegrant, surfactant and diluents. Drug and the Excipients were homogeneously blended and subsequently compressed into tablet (6 mm Punch) using 12 station multi tooling rotary tablet punching machine The levels for the formulation design were as given in table 1. Table 1Formulation variables and their levels for core tablet optimization. Table 2 summarizes the experimental runs, their factor combinations and the translation of the coded levels to the experimental units used in the study. 
Formulation of Press coated tablet:
Powder blend for press-coated tablet was prepared by dry blending together different compositions of the Ethyl cellulose, HPMC, Polyox WSR301, and Xanthan gum as shown in Table 3 . These excipients were dry blended in different weight compositions using surface response design in order to get suitable polymer composition. This composition was dry blended until uniformly blended mixture was obtained. This mixture was then used for the preparation of press -coated tablet using direct compression method (10mm punch). 
Level
Evaluation of press coated tablets
Core tablets and Press Coated Pulsatile Tablets were evaluated for following parameters as per their pharmacopoeial procedures.
Hardness test: It was determined using Monsanto hardness tester [9] [10] [11] .
Friability test: Ten tablets were initially weighed and transferred into Roche friabilator. The friabilator was operated at 25 rpm for 4 minutes [9] [10] [11] .
Weight variation test:
Ten tablets were selected randomly from each formulation and weighed individually to check for weight variation 9-,11 .
In vitro drug release studies: (A) Core Tablets
The in vitro drug release from core tablets was carried out using USP paddle apparatus at 50 rpm and 37±0.5ºC. Phosphate buffer (pH 6.8) was used as the dissolution medium. The samples were withdrawn at regular intervals and analyzed by UV spectrophotometer at 225nm for the presence of the drug. Dissolution tests were performed in triplicate [9] [10] [11] . ISSN: 2250-1177 CODEN (USA): JDDTAO
(B) Press Coated Pulsatile Tablets
The in vitro drug release from coated tablets was carried out using USP paddle apparatus at 50 rpm. HCl (0.1 N) and phosphate buffer (pH 6.8) were used as the dissolution medium. Initially tablets were subjected to dissolution in 0.1 HCl for 2h and after that media were changed to phosphate buffer (pH 6.8). The samples were withdrawn at regular intervals and analyzed by UV spectrophotometer at 225 nm for the presence of the drug. Dissolution tests were performed in triplicate.
RESULT & DISCUSSION: Compatibility Studies
In order to investigate the possible interactions between Montelukast Sodium and polymers and/or diluents, FT-IR of Drug were carried out by using FTIR spectrophotometer (FTIR-8400S)as shown in Fig.1a ,and b. FT-IR results proved that the drug was found to be compatible with excipients as wave numbers are almost similar for pure drug and also drug excipients mixture. 
Precompression Parameters of Core Tablet Powder Blend
Bulk density, tapped density, Hausner's ratio and carr's index given in the Table5.The angle of repose (θ) for all the formulation ranged from 19 to 25° indicating good flow properties. The result of compressibility index was between 12 to 16, which indicates good flow properties & for Hausners ratio was near/less about 1.2 also supported the results of free flowing.
Postcompression Parameters of Core Tablets
The tablet hardness, friability, weight variation of all tablet formulations were found to be satisfactory and reproducible as observed from the data in Table 6 . The hardness of all the tablets was between 3 to 5kg/cm 2 . In the present study, the loss in total weight in friability test was in the range of 0.77 to 0.91% that indicates, the percentage friability for all the formulations was found below 1% indicating that friability (%) is within the acceptable limits. In weight variation test, the pharmacopoeia limit for the percentage deviation for tablets weighing more than50 mg is ±7.5%. The average percentage deviation of all tablet formulations was found to be within limit, and hence all formulations passed the test for uniformity of weight as per official requirement. ISSN: 2250-1177 CODEN (USA): JDDTAO Table5: Evaluation of directly compressible blends of core tablet 
Figure 2a: Percent Drug Release of core tablets
The response surface graph figure 2b shows that as the conc. of superdisentigrants and conc. of surfactant increases % drug release decreased. While with increase in superdisintegrant and decrease in surfactant conc increases the drug release.This might be due to high conc of surfactant drug may be entrapped in surfactant micelles.
Figure 2b: Effect of superdisintegrants and surfactant on drug Release Postcompression Parameters of Press-Coated Tablets
The tablet hardness, friability, weight variation of all tablet formulations were found to be satisfactory and reproducible as observed from the data in Table 7 .The hardness of all the tablets was between7 and 8kg/cm 2 . In the present study, the loss in total weight in friability test was in the range of 0.66 to 0.99% that indicates, the percentage friability for all the formulations was found below 1% indicating that friability (%) is within the acceptable limits. In a weight variation test, the pharmacopoeia limit for the percentage deviation for tablets weighing more than100mg is ±5%. The average percentage deviation of all tablet formulations was found to be within limit, and hence all formulations passed the test for uniformity of weight as per official requirement. ISSN: 2250-1177 CODEN (USA): JDDTAO The percent release of drug for all tablet formulations was found to be satisfactory and reproducible. 
CONCLUSION
Chronopharmaceutical Drug delivery formulations were prepared by direct compression press coating using Response Surface Methodology with polymers as Xanthan gum, Polyox, HPMC & Ethyl Cellulose alone and in combination. Polyox having a property of fast hydration & swelling useful for maintaining lag time.
Xanthan gum has more viscosity on coming in contact with solvent and ethyl cellulose a hydrophobic polymer. So, combinations of these polymers give better lag time.
